Navigation Links
NuvaRing Lawsuit Filed by Alonso Krangle Alleges That Use of NuvaRing Caused a Louisiana Woman to Develop a Life-Threatening Blood Clot Disorder
Date:9/3/2013

New York, NY (PRWEB) September 03, 2013

Alonso Krangle’s lawyers have filed a NuvaRing lawsuit due to a pulmonary embolism on behalf of a woman from Louisiana. This case (Case No. 2:13-cv-02933-SDW-MCA) was filed on May 13, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be Organon USA, Inc. and Merck & Co., Inc. According to the NuvaRing lawsuit complaint, the plaintiff’s use of NuvaRing was directly responsible for her development of a pulmonary embolism.

Additionally, this case contends that Organon and the other defendants knew about but failed to warn the public regarding the fact that NuvaRing has been linked to a higher risk of blood clot-related complications than oral contraceptives. Specifically, this NuvaRing lawsuit claims that the defendants marketed NuvaRing as a safe and effective contraceptive without alerting women about the serious risks of developing blood clots, deep vein thrombosis and/or pulmonary embolism when using NuvaRing.

Alonso Krangle’s experienced defective drug attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

Alleged Injuries in the NuvaRing Lawsuit

According to court documents, the plaintiff started using NuvaRing in July 2009. Within two years of using this contraception, the plaintiff reportedly began to experience chest pain and shortness of breath, which led her to seek medical care for an official diagnosis. After undergoing an x-ray, the plaintiff was told that she had pulmonary embolism and had developed multiple blood clots (emboli) in her lungs. Subsequently, she was hospitalized for one night and was placed on anticoagulation therapy, including Lovenox and Warfarin. While the plaintiff is currently still on this anticoagulation therapy, she has also had to undergo regular follow-up care to monitor her health.

Blood Clot Injuries Linked NuvaRing Use

Use of NuvaRing and the development of serious blood clot disorders like pulmonary embolism has been linked by many researchers within recent years. In fact, a study published in 2012 in the New England Journal of Medicine reported that vaginal rings like NuvaRing could increase women’s risk of developing blood clots by nearly three times, when compared to the risk associated with older birth control pills.
[ http://www.nejm.org/doi/full/10.1056/NEJMoa1111840

Similarly, a study published in the May 2012 British Medical Journal reported that women’s risk of developing blood clots increased by more than 6 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
[ http://www.bmj.com/content/344/bmj.e2990#alternate

The alleged serious risks associated with NuvaRing use seem to be confirmed by data from the FDA’s Adverse Events Reporting System (AERS), which has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). In fact, some of the most commonly reported adverse effects associated with NuvaRing use included more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, more than 30 percent of women who reported NuvaRing complications had to be hospitalized due to the severity of their injuries, and approximately 3 percent of NuvaRing complications resulted in death.
[ http://adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING

About Alonso Krangle LLP And Filing A NuvaRing Blood Clot lawsuit

Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11072883.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NuvaRing Lawsuits Move Forward, as Federal Judge Rejects Motion for Summary Judgment in NuvaRing Lawsuit Bellwether Trial, Wright & Schulte LLC Reports
2. NuvaRing Lawsuit Filed by Alonso Krangle Alleges that a Virginia Woman Developed Pulmonary Embolism Due to NuvaRing Use
3. New NuvaRing Lawsuit on Deep Vein Thrombosis: Now, AttorneyOne Can Provide Advice
4. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman Alleges that NuvaRing Use Caused Her to Develop Serious Blood Clot Disorder, Reports Alonso Krangle
5. New NuvaRing Blood-Clotting Lawsuit Allegations Report: Resource4thePeople Updates Latest Legal Developments as Litigation Proceeds
6. NuvaRing Bellwether Trial Scheduled: Now, AttorneyOne Can Provide Advice
7. NuvaRing Lawsuit Filed by Alonso Krangle on Behalf of a Louisiana Woman Who Developed Pulmonary Embolism Allegedly Due to NuvaRing Use
8. NuvaRing Blood Clot Lawsuit Filed on Behalf of a California Woman Who Developed a Serious Blood Clot Disorder Allegedly Due to Use of NuvaRing, Reports Alonso Krangle
9. NuvaRing Lawsuit News: First New Jersey NuvaRing Trial Scheduled to Start This Week, Rottenstein Law Group LLP Reports
10. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
11. Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology: